Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial
Authors' conclusion
Phentermine-topiramate-ER, when combined with a DELI, produced significant and sustained weight loss and reduced CVD risk in adults with obesity.
Study context
- Population
- Adults with obesity (BMI ≥ 30 kg/m²) in a digitally enhanced lifestyle intervention (DELI) program (in-person and telehealth, diet and activity goals, smartphone app with Apple Watch, Bluetooth weight scale and BP monitor); single tertiary academic center, US, June 2020-June 2022randomized 1:1
- Participants
- 80 adults
- Comparison
- Phentermine-topiramate-ER (7.5/46 mg) vs placebo, both added to a digitally enhanced lifestyle intervention (DELI)
- Phentermine-topiramaten = 42
- Placebon = 38reference
Methodological detailsdouble-blind, placebo-controlled, single-centre, 12-month
- Double-blind
- Placebo-controlled
- Single-centre
- 12-month
Primary result
Weight loss · 12 months
Mean difference
−9.48 kg
P < 0.001
By group
As reported in the abstract
Further findings
| Outcome | Placebo | Mean difference (kg) | P value |
|---|---|---|---|
| Weight loss · 3 monthsPhentermine-topiramate-ER vs Placebo | mean 4.04 kg | −6.78 | P = 0.002 |
- Weight loss: Phentermine-topiramate-ER mean 10.82 kg
Estimated atherosclerotic cardiovascular disease (CVD) risk, change from baseline
- Reduction vs baseline with phentermine-topiramate-ER (p = 0.004)
- 3.35%
Original publication
Addition of Phentermine‐Topiramate to a Digitally Enhanced Lifestyle Intervention: A Double‐Blind Randomized Clinical Trial. Obesity (Silver Spring). Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →